'Shortfall' in Array Business, Customer Delays Force Illumina to Cut Q2 Revenue Guidance

Illumina shed between 4 percent and 7 percent from its original forecast, blaming delays in the start of genome-wide association studies and reduced foundation funding. The updated forecast represents a 15-percent increase over Q2 2008 revenue.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.